Novel ALK inhibitors in clinical use and development

Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Iragavarapu, Chaitanya, Mustafa, Milaim, Akinleye, Akintunde, Furqan, Muhammad, Mittal, Varun, Cang, Shundong, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349797/
https://www.ncbi.nlm.nih.gov/pubmed/25888090
http://dx.doi.org/10.1186/s13045-015-0122-8
_version_ 1782360088028119040
author Iragavarapu, Chaitanya
Mustafa, Milaim
Akinleye, Akintunde
Furqan, Muhammad
Mittal, Varun
Cang, Shundong
Liu, Delong
author_facet Iragavarapu, Chaitanya
Mustafa, Milaim
Akinleye, Akintunde
Furqan, Muhammad
Mittal, Varun
Cang, Shundong
Liu, Delong
author_sort Iragavarapu, Chaitanya
collection PubMed
description Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical development. Two of them, crizotinib and ceritinib, have been approved by FDA for treatment of locally advanced and metastatic NSCLC. More agents (alectinib, ASP3026, X396) with improved safety, selectivity, and potency are in the pipeline. Dual inhibitors targeting ALK and EGFRm (AP26113), TRK (TSR011), FAK (CEP-37440), or ROS1 (RXDX-101, PF-06463922) are under active clinical development.
format Online
Article
Text
id pubmed-4349797
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43497972015-03-06 Novel ALK inhibitors in clinical use and development Iragavarapu, Chaitanya Mustafa, Milaim Akinleye, Akintunde Furqan, Muhammad Mittal, Varun Cang, Shundong Liu, Delong J Hematol Oncol Review Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical development. Two of them, crizotinib and ceritinib, have been approved by FDA for treatment of locally advanced and metastatic NSCLC. More agents (alectinib, ASP3026, X396) with improved safety, selectivity, and potency are in the pipeline. Dual inhibitors targeting ALK and EGFRm (AP26113), TRK (TSR011), FAK (CEP-37440), or ROS1 (RXDX-101, PF-06463922) are under active clinical development. BioMed Central 2015-02-27 /pmc/articles/PMC4349797/ /pubmed/25888090 http://dx.doi.org/10.1186/s13045-015-0122-8 Text en © Iragavarapu et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Iragavarapu, Chaitanya
Mustafa, Milaim
Akinleye, Akintunde
Furqan, Muhammad
Mittal, Varun
Cang, Shundong
Liu, Delong
Novel ALK inhibitors in clinical use and development
title Novel ALK inhibitors in clinical use and development
title_full Novel ALK inhibitors in clinical use and development
title_fullStr Novel ALK inhibitors in clinical use and development
title_full_unstemmed Novel ALK inhibitors in clinical use and development
title_short Novel ALK inhibitors in clinical use and development
title_sort novel alk inhibitors in clinical use and development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349797/
https://www.ncbi.nlm.nih.gov/pubmed/25888090
http://dx.doi.org/10.1186/s13045-015-0122-8
work_keys_str_mv AT iragavarapuchaitanya novelalkinhibitorsinclinicaluseanddevelopment
AT mustafamilaim novelalkinhibitorsinclinicaluseanddevelopment
AT akinleyeakintunde novelalkinhibitorsinclinicaluseanddevelopment
AT furqanmuhammad novelalkinhibitorsinclinicaluseanddevelopment
AT mittalvarun novelalkinhibitorsinclinicaluseanddevelopment
AT cangshundong novelalkinhibitorsinclinicaluseanddevelopment
AT liudelong novelalkinhibitorsinclinicaluseanddevelopment

Ejemplares similares